Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumors”

102 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 102 results

Not applicableStudy completedNCT03012789
What this trial is testing

Surgical Intervention and the NETest

Who this might be right for
Neuroendocrine TumorGastroenteropancreatic
Wren Laboratories LLC 30
Not applicableStudy completedNCT02788565
What this trial is testing

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumours
Ipsen 156
Testing effectiveness (Phase 2)UnknownNCT03457844
What this trial is testing

Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor G3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 60
Not applicableUnknownNCT05268952
What this trial is testing

Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

Who this might be right for
Neuroendocrine Tumors
University Hospital, Antwerp 100
Testing effectiveness (Phase 2)Looking for participantsNCT06840821
What this trial is testing

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Who this might be right for
Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd 156
Testing effectiveness (Phase 2)UnknownNCT04427787
What this trial is testing

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Who this might be right for
Metastatic Well Differentiated Neuroendocrine NeoplasmNeuroendocrine Tumors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 69
Not applicableLooking for participantsNCT07635316
What this trial is testing

Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 4,023
Early research (Phase 1)Study completedNCT05262556
What this trial is testing

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine NeoplasmNeuroendocrine Carcinoma+1 more
Amr Mohamed MD 15
Large-scale testing (Phase 3)Looking for participantsNCT06937905
What this trial is testing

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 129
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Not applicableLooking for participantsNCT07302100
What this trial is testing

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Strasbourg, France 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06790706
What this trial is testing

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Who this might be right for
Peritoneal MesotheliomaGestational Trophoblastic TumorAnaplastic Thyroid Carcinomas+3 more
Hospices Civils de Lyon 27
Early research (Phase 1)Not Yet RecruitingNCT07661420
What this trial is testing

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Who this might be right for
PheochromocytomaParagangliomaNeuroendocrine Tumors+3 more
University of Pennsylvania 16
Not applicableStudy completedNCT05255133
What this trial is testing

Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment

Who this might be right for
Neuroendocrine Tumors
Universiteit Antwerpen 22
Not applicableLooking for participantsNCT06256705
What this trial is testing

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorRadiotherapy
Assistance Publique - Hôpitaux de Paris 80
Testing effectiveness (Phase 2)Ended earlyNCT01994213
What this trial is testing

Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 53
Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Testing effectiveness (Phase 2)Study completedNCT03095274
What this trial is testing

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Neoplasm of Lung
Grupo Espanol de Tumores Neuroendocrinos 126
Next Page